Bioxcel therapeutics announces tranquility in-care pivotal phase 3 trial plan with bxcl501 for agitation associated with alzheimer's dementia

Company plans to initiate trial following recent meeting with fda no fda-approved therapies for acute treatment of aad are currently available new haven, conn., april 10, 2024 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced details regarding the planned design of its upcoming tranquility in-care phase 3 trial to evaluate bxcl501, the company's investigational proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with alzheimer's dementia (aad) in the care setting.
BTAI Ratings Summary
BTAI Quant Ranking